Latest Regulatory News

Page 538 of 907
hummgroup reports a robust 57% increase in FY25 cash profit to $52.9 million, driven by asset growth and operational efficiencies, while navigating regulatory changes and elevated credit losses.
Claire Turing
Claire Turing
28 Aug 2025
humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.
Claire Turing
Claire Turing
28 Aug 2025
Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.
Ada Torres
Ada Torres
28 Aug 2025
Alternative Investment Trust (ASX, AIQ) reported a robust half-year profit increase of 183%, driven by strong gains in its Warana-managed portfolio. The Trust also announced a significant $44.6 million rights issue to fund further investments.
Claire Turing
Claire Turing
28 Aug 2025
Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.
Ada Torres
Ada Torres
28 Aug 2025
RMA Global Ltd reported a 13% revenue increase to $21.1 million in FY25, driven by growth in the US and New Zealand, alongside steady Australian performance. The company also recorded its first full-year positive operating cash flow, marking a significant financial turnaround.
Sophie Babbage
Sophie Babbage
28 Aug 2025
DigiCo Infrastructure REIT confirms its FY25 EBITDA slightly exceeded IPO guidance and aligned with analyst forecasts, attributing recent share price declines to the absence of FY26 earnings guidance.
Victor Sage
Victor Sage
28 Aug 2025
Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.
Ada Torres
Ada Torres
28 Aug 2025
The Agency Group Australia Ltd reported a 12% revenue increase and a return to positive EBITDA in FY2025, driven by record property sales and operational efficiencies, despite a net loss after tax of $5.44 million.
Eva Park
Eva Park
28 Aug 2025
Reef Casino Trust and Iris Cairns Property Pty Ltd have agreed to increase the takeover bid price to $3.87 per unit, boosting the total offer value to approximately A$192.7 million. The unanimous board recommendation and major unitholder support underscore the deal’s momentum amid regulatory conditions.
Victor Sage
Victor Sage
28 Aug 2025
Airtasker Limited reported a 12.8% increase in revenue to $52.6 million for FY25, driven by growth in Australia, the UK, and the US. However, the company’s net loss widened significantly to $37.7 million, reflecting heavy investment in global marketing and media partnerships.
Sophie Babbage
Sophie Babbage
28 Aug 2025
MA Credit Income Trust has closed its Shortfall Offer ahead of schedule after demand exceeded the $190.5 million target, while updating the timetable for its upcoming Entitlement Offer.
Claire Turing
Claire Turing
28 Aug 2025